Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | Inozyme Pharma, Inc. INZY |
Baker Bros. Advisors LP | 0 0.000% |
-2,168,000 (Position Closed) |
Filing History |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | Zymeworks Inc. ZYME |
Baker Bros. Advisors LP | 27,000 0.040% |
-3,787,196 (-99.29%) |
Filing History |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | Mirati Therapeutics, Inc. MRTX |
Baker Bros. Advisors LP | 0 0.000% |
-1,995,200 (Position Closed) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Adaptimmune Therapeutics plc ADAP |
Baker Bros. Advisors LP | 65,815,692 4.800% |
6,830,430 (+11.58%) |
Filing History |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Baker Bros. Advisors LP | 1,680,517 6.100% |
-296,351 (-14.99%) |
Filing History |
| 2024-02-14 4:21 pm Unchanged |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Baker Bros. Advisors LP | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
Baker Bros. Advisors LP | 146,561 4.990% |
63,505 (+76.46%) |
Filing History |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | Aravive, Inc. ARAV |
Baker Bros. Advisors LP | 3,863,568 4.990% |
-722,836 (-15.76%) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Cabaletta Bio, Inc. CABA |
Baker Bros. Advisors LP | 1,457,626 3.400% |
113,626 (+8.45%) |
Filing History |
| 2024-02-14 4:21 pm Unchanged |
2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Baker Bros. Advisors LP | 2,368,378 4.300% |
0 (Unchanged) |
Filing History |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | Heron Therapeutics, Inc. HRTX |
Baker Bros. Advisors LP | 7,881,933 4.990% |
-249,745 (-3.07%) |
Filing History |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | CYTEIR THERAPEUTICS INC CYTT |
Baker Bros. Advisors LP | 0 0.000% |
-2,492,118 (Position Closed) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Cerus Corporation CERS |
Baker Bros. Advisors LP | 19,497,203 10.800% |
395,327 (+2.07%) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | HOOKIPA Pharma Inc. HOOK |
Baker Bros. Advisors LP | 814,899 9.990% |
467,345 (+134.47%) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Immatics N.V. IMTX |
Baker Bros. Advisors LP | 5,838,853 6.900% |
651,772 (+12.57%) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
Baker Bros. Advisors LP | 4,916,095 9.800% |
4,916,095 (New Position) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Nurix Therapeutics, Inc. NRIX |
Baker Bros. Advisors LP | 4,952,452 9.990% |
150,498 (+3.13%) |
Filing History |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | Opthea Limited OPT |
Baker Bros. Advisors LP | 28,100,345 4.200% |
-3,527,499 (-11.15%) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
Baker Bros. Advisors LP | 6,398,365 10.800% |
43,757 (+0.69%) |
Filing History |
| 2024-02-14 4:21 pm Purchase |
2023-12-31 | 13G | Sagimet Biosciences Inc. SGMT |
Baker Bros. Advisors LP | 1,456,518 6.800% |
1,456,518 (New Position) |
Filing History |